Related Experiment Video
Updated: Jul 9, 2026
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
Published on: December 28, 2015
STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma
Natalya Risinskaya1, Yana Mangasarova1, Elena Nikulina1
1National Medical Research Center for Hematology, Ministry of Health of Russian Federation, 125167 Moscow, Russia.
This study investigated genetic markers in primary mediastinal B-cell lymphoma (PMBCL) and found no association between loss of heterozygosity (LOH) or elevated microsatellite alteration at selected tetranucleotides (EMAST) and patient survival outcomes. Microsatellite instability was not a significant factor in this cohort.
Area of Science:
- Oncology
- Genetics
- Immunotherapy
Background:
- Primary mediastinal B-cell lymphoma (PMBCL) is a distinct non-Hodgkin's lymphoma subtype.
- Approximately 50% of PMBCL patients respond to immune checkpoint inhibitor (ICI) therapy.
- No predictive molecular markers for ICI response in PMBCL have been identified.
Purpose of the Study:
- To assess the incidence of loss of heterozygosity (LOH), elevated microsatellite alteration at selected tetranucleotides (EMAST), and microsatellite instability (MSI) in PMBCL.
- To investigate potential associations between these genetic alterations and clinical outcomes in PMBCL patients treated with chemotherapy.
Main Methods:
- Tumor DNA from 72 PMBCL patients was analyzed for LOH, EMAST, and MSI.
- DNA was isolated from diagnostic biopsy samples.
- Short tandem repeat (STR) profiling was performed using PCR and the COrDIS Plus multiplex kit.
Main Results:
- LOH was detected in 51.4% of patients, and EMAST in 55.5%.
- A combination of EMAST and LOH was observed in 24 patients.
- No significant association was found between LOH, EMAST, or MSI and overall or event-free survival in patients treated with R-Da-EPOCH-21 chemotherapy.
Conclusions:
- LOH and EMAST are common genetic alterations in PMBCL.
- These specific genetic markers do not appear to predict clinical outcomes in PMBCL patients receiving standard chemotherapy.
- Further research is needed to identify predictive biomarkers for ICI therapy in PMBCL.
